These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 7487133)

  • 1. [Introduction of a new aromatase inhibitor fadrozole hydrochloride hydsate].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1995 Nov; 22(13):1991-7. PubMed ID: 7487133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical trial of fadrozole hydrochloride for postmenopausal patients with recurrent breast cancer].
    Kanzaki M; Nakaya Y; Kojima K; Toda H; Tobayama S; Machida H; Ohba M
    Gan To Kagaku Ryoho; 1999 Jun; 26(7):959-65. PubMed ID: 10396324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
    Miller AA; Lipton A; Henderson IC; Navari R; Mulagha MT; Cooper J
    Cancer; 1996 Aug; 78(4):789-93. PubMed ID: 8756373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Endocrine therapy for advanced or recurrent breast cancer].
    Sonoo H; Kurebayashi J
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):909-16. PubMed ID: 11478139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A combined effect of fadrozole and tamoxifen in postmenopausal patients with recurrent breast cancer: a preliminary report: Japanese Cooperative Study Group of Fadrozole and Tamoxifen].
    Tominaga T; Kimura M; Toge T; Takashima S; Nomura Y; Ohashi Y
    Gan To Kagaku Ryoho; 2000 Oct; 27(11):1709-18. PubMed ID: 11057322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase inhibitors: rationale for use following antiestrogen therapy.
    Yue W; Santen RJ
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
    Tanaka M; Yano S; Hasegawa Y; Nakao K
    Arzneimittelforschung; 1994 Jun; 44(6):774-8. PubMed ID: 8053980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of aromatase inhibitors in the treatment of advanced breast cancer.
    Trunet PF; Vreeland F; Royce C; Chaudri HA; Cooper J; Bhatnagar AS
    J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):241-5. PubMed ID: 9365196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.
    Hilsenbeck SG; Osborne CK
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1049s-1055s. PubMed ID: 16467123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine therapy for early breast cancer.
    Hussain SA; Williams S; Stevens A; Rea DW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase inhibitors in metastatic breast cancer.
    Buzdar AU; Plourde PV; Hortobagyi GN
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):28-32. PubMed ID: 8824462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on endocrine therapy for breast cancer.
    Buzdar AU; Hortobagyi G
    Clin Cancer Res; 1998 Mar; 4(3):527-34. PubMed ID: 9533518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary experience with pure antiestrogens.
    Howell A
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4369s-4375s; discussion 4411s-4412s. PubMed ID: 11916227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toremifene and letrozole for advanced breast cancer.
    Med Lett Drugs Ther; 1998 Apr; 40(1024):43-5. PubMed ID: 9580744
    [No Abstract]   [Full Text] [Related]  

  • 18. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials.
    Buzdar AU; Smith R; Vogel C; Bonomi P; Keller AM; Favis G; Mulagha M; Cooper J
    Cancer; 1996 Jun; 77(12):2503-13. PubMed ID: 8640699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.
    Raats JI; Falkson G; Falkson HC
    J Clin Oncol; 1992 Jan; 10(1):111-6. PubMed ID: 1530798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma.
    Costa LA; Kopreski MS; Demers LM; Chinchilli VM; Santen RJ; Harvey HA; Lipton A
    Cancer; 1999 Jan; 85(1):100-3. PubMed ID: 9921980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.